Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
GAP-134 · 3 trials · 2 indications
| Arm | Type | Description |
|---|---|---|
| GAP-134 | EXPERIMENTAL | - |
| placebo | PLACEBO_COMPARATOR | - |
| GAP-134, IV and Oral | OTHER | Experimental; Active Comparator; Placebo |
| Name | Type | Description |
|---|---|---|
| GAP-134 | DRUG | - |
| placebo | DRUG | - |
Inclusion 1. Men or women of non childbearing potential (WONCBP) aged 18 to 50 years inclusive at screening. 2. Body mass index (BMI) in the range of 18.0 to 30.0 kg/m2 and body weight ≥50 kg. 3. Healthy as determined by the investigator on the basis of medical history, physical examination, clinic...
| Company | Ticker | Trials | Lead Phase | Drugs |
|---|---|---|---|---|
| Abbott Laboratories | ABT | 5 | - | Undisclosed |
| Medtronic Plc | MDT | 1 | - | Undisclosed |
| Boston Scientific Corporation | BSX | 1 | - | Undisclosed |
| HeartBeam, Inc. | BEAT | 1 | - | Undisclosed |
| Cardio Diagnostics Holdings Inc. | CDIO | 1 | - | Undisclosed |
GAP-134 is an investigational small molecule being studied for the treatment of arrhythmia, a condition involving abnormal heart rhythms. It has also been evaluated in healthy subjects as part of early clinical development. The drug is administered intravenously and is currently in Phase 1 clinical trials.
GAP-134 is being developed by Pfizer, Inc., a biopharmaceutical company listed on the New York Stock Exchange under the ticker symbol PFE. The company has sponsored multiple Phase 1 clinical trials to evaluate the safety, tolerability, and pharmacokinetics of the drug.
GAP-134 is in Phase 1 clinical development. It is an investigational drug and has not been approved by regulatory authorities. All completed trials for GAP-134 are Phase 1 studies, indicating it is still in the early stages of clinical testing.
GAP-134 has been studied in three completed Phase 1 clinical trials. These include NCT00510029, a single ascending dose study in the United States with 72 participants; NCT00543946, a study in healthy Japanese males with 56 participants; and NCT00783341, a study in healthy subjects with 25 participants.
The mechanism of action for GAP-134 has not been disclosed in the available information. As a small molecule being investigated for arrhythmia, it is believed to interact with cardiac targets, but specific molecular targets have not been publicly identified.
No alternative names for GAP-134 have been identified in the available information. The drug is referred to solely as GAP-134 in clinical trial records and development documentation.